BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp, (NYSE: LH), a leading global life sciences company, announced today that Dr. Deborah Ann Sesok-Pizzini has been appointed Chief Medical Officer of Labcorp Diagnostics, following the retirement of Dr. Dot Adcock in April 2021. Dr. Sesok-Pizzini assumed the role starting on January 11, 2021.
Dr. Sesok-Pizzini joins Labcorp with over two decades of experience in healthcare. Prior to joining Labcorp, she held multiple appointments with The Children’s Hospital of Philadelphia, including Patient Safety Officer, Chief of the Division of Transfusion Medicine and Vice-Chief of Pathology and Laboratory Medicine. She was also a professor of clinical pathology and laboratory medicine at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA.
“We are thrilled to welcome Dr. Sesok-Pizzini to Labcorp,” said Dr. Brian Caveney, chief medical officer and president of Labcorp Diagnostics. “Her significant contributions to scientific communities and research, along with her esteemed career in healthcare and pathology, will provide invaluable expertise and insight to our leadership team. We are also extremely grateful to Dr. Dot Adcock for her dedication and years of stellar service to Labcorp and wish her the best in retirement.”
Dr. Sesok-Pizzini holds her doctorate from Pennsylvania State University and a MBA from Villanova University. She belongs to an extensive list of professional and scientific organizations and has authored dozens of articles, abstracts and publications related to her research.
“I am excited to be joining Labcorp Diagnostics and look forward to helping further the mission to improve health and improve lives,” said Dr. Sesok-Pizzini. “My top priority has always been the patient. I hope to use my experiences and education to provide insights that can be used to enhance the patient experience, enable health provider decisions and develop innovative testing solutions.”
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives. With over 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $11.5 billion in FY2019. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to clinical laboratory testing and the potential benefits of a COVID-19 test home collection kit and our responses to and the expected future impacts of the COVID-19 pandemic and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, whether our response to the COVID-19 pandemic will prove effective, the impact of the COVID-19 pandemic on our business and financial condition, as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.